PMID- 10369466
OWN - NLM
STAT- MEDLINE
DCOM- 19990901
LR  - 20181113
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 127
IP  - 1
DP  - 1999 May
TI  - Effect of the neuroprotective compound SR57746A on nerve growth factor synthesis 
      in cultured astrocytes from neonatal rat cortex.
PG  - 139-44
AB  - The neurotrophic factor promoting activity of the neuroprotective compound 
      SR57746A was evaluated in primary cultures of neonatal rat cortical astrocytes by 
      studying the synthesis of nerve growth factor (NGF) and brain-derived 
      neurotrophic factor (BDNF). A concentration- and time-dependent increase of nerve 
      growth factor mRNA was induced by SR57746A (10 nM-1 microM). In these astrocytes, 
      BDNF mRNA contents were increased to a significant but smaller extent, and 
      beta-actin mRNA showed no variation. SR57746A (1 microM) induced increases of 
      both de novo protein translation after 6 h of incubation and NGF release into the 
      extracellular medium after 6-24 h. These effects were preceded by a transient 
      augmentation of junB, c-fos and c-jun mRNA contents. These increases of AP-1 
      family mRNA were associated with increased nuclear AP-1 binding activity. The 
      results show that SR57746A can increase the synthesis and release of NGF in rat 
      cortical astrocytes. Such effects may contribute to the drug's previously 
      described neuroprotective effects.
FAU - Labie, C
AU  - Labie C
AD  - Department of Neuropsychiatry Research, Sanofi Recherche, Toulouse, France. 
      christophe.labie@sanofi.com
FAU - Lafon, C
AU  - Lafon C
FAU - Marmouget, C
AU  - Marmouget C
FAU - Saubusse, P
AU  - Saubusse P
FAU - Fournier, J
AU  - Fournier J
FAU - Keane, P E
AU  - Keane PE
FAU - Le Fur, G
AU  - Le Fur G
FAU - Soubrie, P
AU  - Soubrie P
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Naphthalenes)
RN  - 0 (Nerve Growth Factors)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Pyridines)
RN  - 0 (RNA, Messenger)
RN  - 0 (Transcription Factor AP-1)
RN  - EC 3.1.30.1 (Single-Strand Specific DNA and RNA Endonucleases)
RN  - V8QL94KNQO (xaliproden)
SB  - IM
MH  - Animals
MH  - Animals, Newborn
MH  - Astrocytes/drug effects/*metabolism
MH  - Brain-Derived Neurotrophic Factor/biosynthesis/genetics
MH  - Cells, Cultured
MH  - Cerebral Cortex/cytology/drug effects/*metabolism
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Naphthalenes/*pharmacology
MH  - Nerve Growth Factors/*biosynthesis/genetics
MH  - Neuroprotective Agents/*pharmacology
MH  - Precipitin Tests
MH  - Protein Biosynthesis
MH  - Pyridines/*pharmacology
MH  - RNA, Messenger/biosynthesis
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Single-Strand Specific DNA and RNA Endonucleases/metabolism
MH  - Transcription Factor AP-1/metabolism
PMC - PMC1566010
EDAT- 1999/06/16 00:00
MHDA- 1999/06/16 00:01
PMCR- 2000/05/01
CRDT- 1999/06/16 00:00
PHST- 1999/06/16 00:00 [pubmed]
PHST- 1999/06/16 00:01 [medline]
PHST- 1999/06/16 00:00 [entrez]
PHST- 2000/05/01 00:00 [pmc-release]
AID - 0702545 [pii]
AID - 10.1038/sj.bjp.0702545 [doi]
PST - ppublish
SO  - Br J Pharmacol. 1999 May;127(1):139-44. doi: 10.1038/sj.bjp.0702545.